YUHAN CORPORATION
Financials
Valuation Metrics
YUHAN CORPORATION's Market Cap is ₩5.7T. At end of 2025 it was ₩8.4T. Ranked #90 of 2,410 in KR market (top 4%), #85 of 779 on KOSPI (top 11%), #6 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.68T KRW | KR#90/2,410 Sec#6/231 |
| Revenue | 2.28T KRW | KR#234/2,410 Sec#4/231 |
| Net Income | 222.72B KRW | KR#133/2,410 Sec#5/231 |
| Total Assets | 3.33T KRW | KR#225/2,410 Sec#6/231 |
| Net Assets | 2.47T KRW | KR#156/2,410 Sec#4/231 |
| Employees | 2,117 | KR#133/2,410 Sec#6/231 |
| Value | ||
| P/E | 25.56x | KR#1,284/2,410 Sec#78/231 |
| P/B | 2.30x | KR#2,045/2,410 Sec#157/231 |
| PEG | 0.14x | KR#511/2,410 Sec#28/231 |
| P/S | 2.49x | KR#1,943/2,410 Sec#115/231 |
| EV/EBITDA | 45.29x | KR#1,337/2,410 Sec#86/231 |
| FCF Yield | 0.12% | KR#1,208/2,410 Sec#92/231 |
| Profitability | ||
| ROE | 9.01% | KR#699/2,410 Sec#49/231 |
| ROA | 6.69% | KR#552/2,410 Sec#44/231 |
| Op. Margin | 5.42% | KR#909/2,410 Sec#68/231 |
| Revenue Growth | 5.40% | KR#1,169/2,410 Sec#115/231 |
| Earnings Growth | 178.66% | KR#261/2,410 Sec#16/231 |
| Financial Health | ||
| Debt Ratio | 34.77% | KR#685/2,410 Sec#83/231 |
| Total Debt | 349.53B KRW | KR#370/2,410 Sec#18/231 |
| FCF | 6.63B KRW | KR#831/2,410 Sec#54/231 |
| Cash | 427.95B KRW | KR#158/2,410 Sec#2/231 |
| Current Ratio | 2.27x | KR#764/2,410 Sec#91/231 |
| Net Debt/EBITDA | -0.63x | KR#461/2,410 Sec#26/231 |
| Dividend | ||
| Div. Yield | 0.79% | KR#1,195/2,410 Sec#71/231 |
| Div. Growth | 20.00% | KR#437/2,410 Sec#23/231 |
| Performance | ||
| 1Y Return | -35.42% | KR#1,591/2,410 Sec#129/231 |
| 1M Return | 2.83% | KR#237/2,410 Sec#26/231 |
| From 52W High | -41.02% | KR#797/2,410 Sec#58/231 |
| 1Y MDD | -46.88% | KR#818/2,410 Sec#64/231 |
| Trading | ||
| Volume | 182,000 shares | KR#396/2,410 Sec#42/231 |
| Trading Value | 13.98B KRW | KR#140/2,410 Sec#8/231 |
| Foreign Own. | 21.26% | KR#209/2,410 Sec#9/231 |
| Per Share | ||
| EPS | 2,982 KRW | KR#340/2,410 Sec#22/231 |
| BPS | 33,079 KRW | KR#345/2,410 Sec#23/231 |
Company Info
Established in 1926 and listed on the securities market in 1962, the company is a leading pharmaceutical firm, with 14 companies under its umbrella, including a subsidiary slated for KOSDAQ listing in 2025. Its primary business is the manufacturing and sale of pharmaceuticals and chemical products, including key products like Leclaza. The company is building an innovative network by adopting AI and big data for new drug development, collaborating with global pharmaceutical companies, and conducting joint R&D with bio-ventures and universities. The company is headquartered in Dongjak-gu, Seoul.